Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Somatostatin × NET × Clear all

Phase

Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 2 Al18F-NOTA-octreotide 2 lutetium Lu 177 dotatate 1 Somatostatin 1 Sirolimus 1 Positron Emission Tomography Computed Tomography 1 Oxaliplatin 1 Leucovorin 1 Injections 1 Fluorouracil 1 Bevacizumab 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06855095 2025-03-03

ATSA

The Netherlands Cancer Institute

Phase 2/3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡